Hey, did you hear about Shuttle Pharma? They’re making huge progress in cancer treatment! They just dosed their first three patients in a Phase 2 clinical trial for Ropidoxuridine, this breakthrough drug that could help treat glioblastoma – one of the deadliest brain cancers. They’ve set up partnerships with six top cancer centers, like Georgetown and UNC, to get more patients into the trial.
What’s amazing is they’ve also managed to clear a big chunk of debt and raised $4.5 million to keep funding the trial. Their CEO, Dr. Anatoly Dritschilo, said it’s a huge milestone for both the company and for patients with few options. The trial is expected to wrap up in a couple of years, and if this works, it could seriously change things for people facing this awful disease.
